Amplifold GmbH is a diagnostic startup based in Martinsried near Munich that develops next-generation ultrasensitive rapid tests. Using a proprietary DNA-origami platform, Amplifold amplifies the signal of conventional lateral flow assays by several orders of magnitude without changing their ease of use or cost advantages. This enables the detection of pathogens, biomarkers and other target molecules with near-laboratory sensitivity directly at the point of care. The technology is designed as an upgrade for existing LFA products and targets applications in in vitro diagnostics, life sciences and beyond. Amplifold’s mission is to make reliable diagnostics available anytime and anywhere.

What drives us as founders of Amplifold is the conviction that reliable diagnostics must not be a luxury, but a fundamental part of good medical care – everywhere in the world. Coming from research, we have seen the vast potential of modern nanotechnology that often never reaches patients in everyday life. With Amplifold, we want to close this gap: we bring near-laboratory precision into a simple, rapid test format that can be used without specialized equipment. We are motivated by the idea that our technology can help detect diseases earlier, guide therapies more precisely, and relieve healthcare systems. What matters most to us is combining scientific excellence with real-world impact – in the lab, in the doctor’s office, and far beyond.